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Apocynin and ebselen reduce 
influenza A virus-induced lung 
inflammation in cigarette smoke-
exposed mice
L. C. Oostwoud1,2, P. Gunasinghe1, H. J. Seow3, J. M. Ye3, S. Selemidis4, S. Bozinovski1,3 & 
R. Vlahos1,3
Influenza A virus (IAV) infections are a common cause of acute exacerbations of chronic obstructive 
pulmonary disease (AECOPD). Oxidative stress is increased in COPD, IAV-induced lung inflammation 
and AECOPD. Therefore, we investigated whether targeting oxidative stress with the Nox2 oxidase 
inhibitors and ROS scavengers, apocynin and ebselen could ameliorate lung inflammation in a mouse 
model of AECOPD. Male BALB/c mice were exposed to cigarette smoke (CS) generated from 9 cigarettes 
per day for 4 days. On day 5, mice were infected with 1 × 104.5 PFUs of the IAV Mem71 (H3N1). BALF 
inflammation, viral titers, superoxide production and whole lung cytokine, chemokine and protease 
mRNA expression were assessed 3 and 7 days post infection. IAV infection resulted in a greater 
increase in BALF inflammation in mice that had been exposed to CS compared to non-smoking mice. 
This increase in BALF inflammation in CS-exposed mice caused by IAV infection was associated with 
elevated gene expression of pro-inflammatory cytokines, chemokines and proteases, compared to 
CS alone mice. Apocynin and ebselen significantly reduced the exacerbated BALF inflammation and 
pro-inflammatory cytokine, chemokine and protease expression caused by IAV infection in CS mice. 
Targeting oxidative stress using apocynin and ebselen reduces IAV-induced lung inflammation in CS-
exposed mice and may be therapeutically exploited to alleviate AECOPD.
Chronic Obstructive Pulmonary Disease (COPD) is a major incurable disease and is the 4th leading cause of 
death worldwide1. COPD is a “disease characterized by airflow limitation that is not fully reversible. The airflow 
limitation is usually progressive and associated with an abnormal inflammatory response of lungs to noxious 
particles and gases”2. Cigarette smoking is the major cause of COPD and accounts for more than 95% of cases in 
industrialized countries3, but other environmental pollutants are important causes in developing countries4. In 
addition, increased oxidative stress plays a key role in the progression of the inflammatory process5. The abnor-
mal inflammatory response in the lungs of COPD patients consists of an influx of macrophages, neutrophils, 
T lymphocytes and increased levels of pro-inflammatory cytokines (e.g. tumour necrosis factor-α [TNF-α ], 
interleukin-8 [IL-8], granulocyte-macrophage colony stimulating factor [GM-CSF])6, chemokines (e.g. monocyte 
chemoattractant protein-1 [MCP-1] and matrix metalloproteinases (e.g. MMP-1, -9 and -12)6. Current pharma-
cological therapies do not effectively relieve the symptoms, inflammation and decline in lung function in COPD6.
Importantly, patients with COPD are susceptible to acute exacerbations of COPD (AECOPD), defined 
as “a sustained worsening of patient’s condition from the stable state and beyond normal day-day variations 
that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD”7. 
Exacerbations are a common occurrence in COPD patients and contribute mainly to morbidity, mortality and 
reduced health7. During AECOPD, there are increased levels of neutrophils and macrophages and up-regulation 
of IL-6, IL-8, TNF-α , interferon gamma (IFN)-γ , GM-CSF and MMP-12 in sputum7,8. Moreover, there is 
increased activation of nuclear factor–ĸB (NF-ĸB) in alveolar macrophages, and expression of inflammatory 
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markers such as TNF-α and IL-86,8. AECOPD are due to a number of aetiological factors, predominantly viral 
and bacterial infections with 40–60% attributed to viral infections7. The majority of these infections are due to 
respiratory syncytial virus (RSV) (22%), influenza A (25%) and rhinovirus (36%)9. Even though RSV is the most 
commonly isolated virus in exacerbations, influenza has the potential to be more problematic due to the likeli-
hood of epidemics and pandemics7.
Previous studies have shown that prior cigarette smoke (CS) exposure exacerbates lung inflammation and 
disrupts the resolution of influenza infection in mice10,11. Current treatments to combat influenza outbreaks are 
primarily focused on targeting the mechanisms of viral infection and replication. Strain-specific vaccines and 
anti-viral drugs, such as Relenza and Tamiflu, have some efficacy in the treatment and/or prevention of influenza 
infection12,13. However, evidence suggests that current treatments are problematic due to the ability of influenza 
to develop resistance against anti-viral therapeutics14. In addition, the effectiveness of vaccination depends on 
patient’s immune status, age, and co-morbidities15.
Oxidative stress, which is defined as the persistent overproduction of reactive oxygen species (ROS) that 
overwhelms endogenous antioxidant defence systems, has been shown to play a role in COPD, AECOPD and 
influenza A virus (IAV)-induced lung inflammation and damage12,16–18. There is an increased oxidant burden in 
smokers resulting from the fact that CS itself contains over 4700 different chemical compounds and more than 
1015 oxidants/free radicals per puff16,19–21. These oxidants can give rise to additional ROS generated enzymatically 
by inflammatory and epithelial cells within the lung as part of an inflammatory-immune response towards a path-
ogen or irritant. Activation of macrophages and neutrophils by CS generates superoxide radicals (O2●−), which 
can then either react with nitric oxide (NO) to form reactive peroxynitrite molecules (ONOO−) or alternatively 
be rapidly converted to damaging hydrogen peroxide (H2O2) under the influence of superoxide dismutase (SOD). 
This in turn can result in the non-enzymatic production of the more damaging hydroxyl radical (●OH) from H2O2 
in the presence of Fe2+ through the Fenton reaction. Nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidases are the major enzymatic sources of superoxide production by inflammatory cells13,22,23.
Increased levels of ROS have been implicated in initiating inflammatory responses in the lungs through the 
activation of transcriptional factors such as NF-κ B and activator protein-1 (AP-1), signal transduction pathways, 
chromatin remodelling and gene expression of pro-inflammatory mediators16,17,24. Oxidative stress can cause 
deleterious effects in the body such as DNA damage, lipid peroxidation and protein denaturation25. Moreover, 
oxidative stress can affect remodelling of extracellular matrix, mitochondrial respiration, and protective mech-
anisms of the lung such as the surfactants to increase the strength of alveoli16. During COPD exacerbations, the 
newly recruited neutrophils activate oxidant-sensitive transcription factors leading to increased transcription 
of pro-inflammatory genes resulting in oxidative burst26. Moreover, there is an increased concentration of H2O2 
in exhaled breath condensate (EBC) of COPD patients and this is further elevated during AECOPD3,26. H2O2 
can activate NF-κ B resulting in pro-inflammatory gene activation, thereby worsening the condition27,28. The 
glutathione system is the major anti-oxidant mechanism in the airways and is upregulated in response to CS3. 
However, during severe COPD exacerbations anti-oxidant enzymes such as glutathione peroxidase (GPx) are 
depleted leading to increased oxidative stress3,26. We have previously shown that GPx-1 deficient mice exposed to 
CS have enhanced BALF inflammation suggesting GPx-1 has a protective role against CS-induced lung inflam-
mation29. More recently, we showed that GPx-1 protects against IAV-induced lung inflammation30. The GPx 
mimetic ebselen has been shown to reduce sephadex-31, LPS-32 and CS-induced lung inflammation29. We have 
also shown that mice deficient in Nox2 had markedly reduced superoxide radicals production and lung inflam-
mation following IAV infection18. Apocynin, an NADPH oxidase-2 inhibitor, significantly reduced IAV-induced 
lung inflammation, superoxide production and viral titres18. Stefanska et al. have recently shown that apocynin 
treatment reduced the H2O2 concentrations in EBC of COPD patients in comparison to the placebo group33. 
Moreover, apocynin inhalation decreased the concentrations of nitrite in airways of COPD patients, implying 
apocynin could be considered as an anti-inflammatory agent in COPD34.
Therefore, given that there is increased oxidative stress in AECOPD, and that ROS such as superoxide and 
H2O2 are elevated in human AECOPD, we investigated whether targeting the production of ROS with apocynin 
(a small molecule that inhibits NADPH oxidase assembly) and ebselen (an active organo-selenium compound 
that mimics the action of GPx) can reduce lung inflammation in an animal model of AECOPD.
Methods
Animals. Specific pathogen-free BALB/c mice aged 7–9 weeks and weighing ~20 g were obtained from the 
Animal Resource Centre Pty Ltd (Perth, Australia). The animals were housed at 20 °C on a 12-h day/night cycle 
in sterile micro-isolators and fed a standard sterile diet of Purina mouse chow with water allowed ad libitum. The 
experiments described in this manuscript were approved by the Animal Ethics Committee of The University of 
Melbourne (Application ID 1112185) and conducted in compliance with the guidelines of the National Health 
and Medical Research Council of Australia on animal experimentation.
Cigarette smoke exposure. Mice were placed in an 18-L perspex chamber (The Plastic Man, Huntingdale, 
Victoria, Australia) in a class II biosafety cabinet (AES Environmental Pty Ltd, Melbourne, Victoria, Australia) 
and exposed to CS generated from 9 cigarettes per day for 4 days as previously described35,36. Briefly, mice were 
exposed to CS generated from 9 cigarettes/day for 4 days, delivered three times per day at 9 AM, 12 noon and 
3 PM with 3 cigarettes spaced over 1 h. Smoke was generated in 50-ml tidal volumes over 10 s, by use of timed 
draw-back mimicking normal smoking inhalation volume and cigarette burn rate. The mean total suspended 
particulate mass concentration in the chamber containing CS was ~420 mg m−3. Sham-exposed mice were placed 
in an 18-L perspex chamber but did not receive CS. Commercially available filter-tipped Winfield Red cigarettes 
(manufactured by Philip Morris, Australia) of the following composition were used: 16 mg or less of tar, 1.2 mg or 
less of nicotine, and 15 mg or less of CO.
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Influenza A virus infection. After 4 days of CS or sham exposure, mice were anaesthetized by placing 
them in a small plastic container with cotton gauze onto which 2 ml of methoxyflurane (Medical Developments 
International Ltd, Australia) had been applied. Anaesthetized mice were infected intranasally with 1 × 104.5 
plaque forming units (PFU) of the intermediate virulent IAV Mem71 (H3N1) in a 30 μ l volume, diluted in PBS. 
Control animals were given 30 μ l of PBS + VP-SFM vehicle (diluent). Mice were then culled 3 and 7 days (d3 
and d7) after viral infection. The time points of 3 and 7 days post infection are based on our previous studies 
and represent the peak and resolution (respectively) of influenza infection10. There was no further CS exposure 
after IAV infection. Mouse body weight, food consumption and the well-being of mice were monitored daily at 
approximately the same time, to ensure that mice were not going through severe distress in response to CS and 
IAV infection. Food consumption was calculated by measuring the amount of food remaining in cages every 24 h 
and dividing that by the number of mice in the cages.
Ebselen and apocynin treatment. Mice were treated once a day with ebselen (10 mg kg−1) or vehicle 
(5% carboxymethyl [CM]-cellulose made up in distilled water) via oral gavage 3 h before IAV infection and daily 
thereafter until they were killed 3 and 7 days post infection. In separate experiments, mice were treated with 
apocynin (5 mg kg−1) or vehicle (0.1% Dimethyl Sulfoxide [DMSO] in PBS) administered via intraperitoneal 
injection (i.p.) 3 h prior to IAV infection and daily thereafter until they were killed 3 and 7 days post infection. The 
doses for both apocynin and ebselen are based on our previous publications18,29,30.
Bronchoalveolar lavage and lung collection. Animals were culled by i.p. injection of sodium pentobar-
bitone (360 mg kg−1) (Sigma Aldrich, St. Louis, MO) on day 3 or day 7 post infection. Lungs were then lavaged 
in situ with a 400 μ l aliquot of PBS, followed by three 300 μ l aliquots as previously described35,36. In total up to 1 ml 
of bronchoalvealor lavage fluid (BALF) was retrieved per mouse. The total number of viable cells in the BALF was 
determined, cytospins were prepared using 50–200 μ l of BALF, and cells were differentiated by standard morpho-
logical criteria. Residual BALF was centrifuged to collect the supernatant for storage at − 80 °C. Whole lungs were 
perfused free of blood via right ventricular perfusion with 5 ml of PBS, rapidly excised en bloc, rinsed in PBS, 
blotted, snap frozen in liquid nitrogen and stored at − 80 °C.
RNA extraction and quantitative real-time PCR. Total RNA was extracted from approximately 15 mg 
of whole lung tissue pooled from five to eight mice per treatment group using RNeasy Mini Kits (Qiagen, Hilden 
Germany), reverse transcribed with High Capacity RNA-to-cDNA kit (Life Technologies, Carlsbad, CA), and 
duplicate real-time PCR reactions with Life Technologies pre-developed Taqman assay reagents were performed. 
18 S rRNA was used as the internal control as previously described35,36. The threshold cycle (CT) value is the PCR 
cycle number (out of 40) at which the measured fluorescent signal exceeds a calculated background threshold 
identifying amplification of the target sequence value and is proportional to the number of input target copies 
present in the sample. CT numbers were transformed with the Δ Δ CT (threshold cycle time) and relative value 
method and were expressed relative to 18S rRNA levels.
Lung homogenization and virus titrations. Lungs from terminally anesthetized IAV-infected mice were 
removed, rinsed in PBS, weighed, and homogenized in 1 ml of Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Life Technologies, Carlsbad, CA). Clarified homogenate was snap frozen and stored at − 80 °C until required. 
Virus was quantitated by plaque assay in MDCK cells as previously published10,18,30.
Superoxide detection with L-O12 enhanced chemiluminescence. BALF inflammatory cells were 
exposed to the chemiluminescent probe, L-O12 (100 mM; Wako Laboratories, Japan) in the absence (for basal 
measurements) or presence of the PKC and NADPH oxidase activator, phorbol 12, 13 dibutyrate (PDBu, 1 mM; 
Sigma) and dispensed into 96 well white opti-plates for luminescence reading with the TopCount (Perkin Elmer 
Packard). Photon emission was recorded from each well every 2 min and averaged over 45 min. Individual data 
points for each group were derived from the average of 2 replicates, subtracted against the average background 
values and normalized for total cell numbers and expressed as relative light units (RLU). We have previously 
shown incubation of cells with superoxide dismutase (SOD; 600 U/ml) to inactivate superoxide almost abolishes 
the chemiluminescence signal verifying that the L-O12 chemiluminescence signal was due to superoxide18.
Statistical analysis. Data are presented as grouped data expressed as mean ± standard error of the mean 
(SEM); n represents the number of mice per treatment group. Differences were determined by two-way analysis 
of variance (ANOVA) followed by Bonferroni post hoc tests for multiple comparisons. In some cases, Student’s 
unpaired t-test was used to determine if there were significant differences between means of pairs. All statistical 
analyses were performed using GraphPad Prism for Windows (Version 5.03). Statistical significance was indi-
cated by using P < 0.05.
Results
Apocynin reduces BALF inflammation in cigarette smoke exposed and influenza A virus-in-
fected mice. Mice exposed to CS and treated with diluent had a small increase in BALF total cell num-
ber, macrophages and neutrophils when compared to sham + diluent mice at day 3 (Fig. 1). Sham mice treated 
with IAV + vehicle had significantly more BALF total cells, macrophages, neutrophils and lymphocytes com-
pared to sham + diluent + vehicle mice 3 days post infection (Fig. 1). However, CS-exposed mice treated with 
IAV had significantly more BALF total cells, macrophages, neutrophils and lymphocytes when compared to 
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sham + IAV + vehicle mice (Fig. 1) (n = 5–8, P < 0.05). Administration of apocynin (5 mg kg−1) for 3 days caused 
a significant decrease in BALF total cells, macrophages, neutrophils and lymphocytes in CS + IAV mice compared 
to CS + IAV + vehicle mice (Fig. 1) (n = 6–8, P < 0.05).
As in the d3 experiment, d7 CS + IAV mice had significantly more BALF total cells, macrophages, neutrophils 
and lymphocytes when compared to sham + IAV + vehicle mice (Fig. 2) (n = 5–8, P < 0.05). Administration of 
apocynin (5 mg kg−1) for 7 days caused a significant decrease in BALF total cells, macrophages, neutrophils and 
lymphocytes in CS + IAV mice compared to CS + IAV + vehicle mice (Fig. 2) (n = 6–8, P < 0.05). However on 
d7 cell counts were lower than on d3 and therefore show that resolution of inflammation has occurred during 
these days.
Effect of apocynin on chemokine, cytokine and protease mRNA expression in cigarette smoke 
exposed and influenza A virus-infected mice. To identify which mediators drive the enhanced lung 
inflammation in response to CS and IAV infection, mRNA levels of a panel of inflammatory chemokines, 
cytokines and proteases implicated in COPD and IAV infection were measured in whole lung by Q-PCR at both 
3 and 7 days post infection.
Three days post infection, CS + IAV mice had increased mRNA expression of pro-inflammatory chemok-
ines (CCL-2, CXCL-2), cytokines (GM-CSF, TNF-α , IL-1β , IL-6) and proteases (MMP-12) compared to 
sham + IAV + diluent mice (Table 1). However, CS + IAV mice treated with apocynin for 3 days had markedly 
reduced mRNA expression of chemokines (CCL-2, CXCL-2), cytokines (GM-CSF, TNF-α , IL-1β , IL-6) and pro-
teases (MMP-12) compared to CS + IAV + vehicle mice (Table 1).
Seven days post infection, CS + IAV mice had increased mRNA expression of pro-inflammatory chemok-
ines (CCL-2, CXCL-2), cytokines (GM-CSF, TNF-α , IL-1β , IL-6) and proteases (MMP-12) compared to 
sham + IAV + diluent mice (Table 2). However, CS + IAV mice treated with apocynin 7 days had markedly 
reduced mRNA expression of chemokines (CCL-2, CXCL-2), cytokines (GM-CSF, TNF-α , IL-1β , IL-6) and pro-
teases (MMP-12) compared to CS + IAV + vehicle mice (Table 2).
Effect of apocynin on viral load in cigarette smoke  exposed and influenza A virus-infected 
mice. As seen in Fig. 3A, there was a considerable amount of virus present in sham + IAV and smoke + IAV 
mice at d3. However, apocynin (5 mg kg−1) treatment had no effect on viral titres in either IAV-treated nor 
CS + IAV mice (n = 6, P > 0.05).
Figure 1. The effect of 3 day apocynin (5 mg kg−1) administration on BALF cells in mice after exposure to 
cigarette smoke (CS) and infection with influenza A virus (IAV). BALF cellularity is shown as (A) the total 
number of cells, (B) macrophages, (C) neutrophils and (D) lymphocytes. Data are expressed as mean ± SEM 
for n = 5–8 per treatment group. Two-way ANOVA with Bonferroni post-hoc test was performed to assess 
statistical significance. **P < 0.01, ***P < 0.001, #P < 0.05, ###P < 0.001.
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Apocynin reduces superoxide production in mice exposed to cigarette smoke and infected with 
influenza A virus. Basal levels of superoxide were similar for all treatment groups. BAL cells isolated from d3 
IAV-infected mice showed a significant increase in phorbol 12, 13 dibutyrate (PDBu)-stimulated superoxide pro-
duction compared to basal (Fig. 4A) (n = 5–6, P < 0.001). In addition, BAL cells isolated from CS-exposed mice 
infected with IAV had even greater PDBu-stimulated superoxide production compared to IAV-infected mice. 
Figure 2. The effect of 7 day apocynin (5 mg kg−1) administration on BALF cells in mice after exposure to 
cigarette smoke (CS) and infection with influenza A virus (IAV). BALF cellularity is shown as (A) the total 
number of cells, (B) macrophages, (C) neutrophils and (D) lymphocytes. Data are expressed as mean ± SEM 
for n = 5–8 mice per treatment group. Two-way ANOVA with Bonferroni post-hoc test was performed to assess 
statistical significance. *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.05, ###P < 0.001.
Treatment
Gene
Sham CS
Dil + Veh Dil + Apo IAV + Veh IAV + Apo Dil + Veh Dil + Apo IAV + Veh IAV + Apo
Cytokines
 GM-CSF 1.00 0.31 3.31 1.79 5.24 5.10 4.11 0.67
 TNF-α 1.00 0.03 0.96 1.16 0.47 0.37 2.72 0.68
 IL-1β 1.00 0.04 4.87 3.22 1.07 0.85 4.57 0.76
 IL-6 1.00 0.04 15.89 14.89 0.43 0.85 24.58 4.51
Chemokines
 CCL-2 1.00 0.60 121.31 124.08 20.06 12.64 377.65 42.93
 CXCL-2 1.00 0.15 15.97 7.09 6.77 5.36 23.98 4.21
 CXCL-10 1.00 1.01 124.63 148.21 4.50 4.35 267.02 87.84
Proteases
 MMP-12 1.00 0.09 2.24 1.41 14.33 16.54 21.84 3.38
Table 1.  Effect of apocynin administration on whole lung cytokine, chemokine and protease mRNA 
expression in cigarette smoke (CS) and influenza A virus (IAV)-infected mice (3 days post infection). 
mRNA expression for all genes was measured simultaneously under identical conditions using quantitative 
real-time PCR. Responses for each time point are shown as fold change relative to sham + dil + veh mice after 
normalization to 18S rRNA (housekeeping gene). Data are shown as the average for duplicate reactions of 6–8 
pooled whole lungs.
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Apocynin (5 mg kg−1) treatment caused a significant reduction in PDBu-stimulated superoxide in IAV-infected 
mice and CS + IAV mice (Fig. 4A) (n = 9–12, P < 0.001).
Treatment
Gene
Sham CS
Dil + Veh Dil + Apo IAV + Veh IAV + Apo Dil + Veh Dil + Apo IAV + Veh IAV + Apo
Cytokines
 GM-CSF 1.00 2.20 1.44 1.20 1.44 1.72 2.80 1.45
 TNF-α 1.00 6.33 38.19 27.17 4.58 6.48 135.90 34.67
 IL-1β 1.00 0.24 3.6 1.58 1.96 3.06 36.60 18.57
 IL-6 1.00 1.75 8.94 7.14 2.14 2.14 24.38 7.62
Chemokines
 CCL-2 1.00 3.02 109.74 84.04 3.85 2.7 132.1 94.8
 CXCL-2 1.00 1.92 3.48 1.36 0.64 0.69 4.57 2.55
 CXCL-10 1.00 0.55 96.53 44.79 0.88 0.53 64.41 49.69
Proteases
 MMP-12 1.00 2.73 18.55 8.19 31.04 46.23 74.69 39.72
Table 2.  Effect of apocynin administration on whole lung cytokine, chemokine and protease mRNA 
expression in cigarette smoke (CS) and influenza A virus (IAV)-infected mice (7 days post infection). 
mRNA expression for all genes was measured simultaneously under identical conditions using quantitative 
real-time PCR. Responses for each time point are shown as fold change relative to sham + dil + veh mice after 
normalization to 18S rRNA (housekeeping gene). Data are shown as the average for duplicate reactions of 6–8 
pooled whole lungs.
Figure 3. Effect of apocynin (A) and ebselen (B) on lung viral titres in mice exposed to cigarette smoke (CS) 
and infected with influenza A virus (IAV). Lung viral titres were determined by plaque assays on individual 
lung homogenates from IAV-infected mice. Data in plaque forming units (PFU) per gram of lung are expressed 
as mean ± SEM for n = 4–6 mice, 3 days post infection. Two-way ANOVA with Bonferroni post-hoc test was 
performed to assess statistical significance. *P < 0.05, ***P < 0.001.
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As with the d3 IAV-infected mice, d7 IAV-infected mice showed a significant increase in PDBu-stimulated 
superoxide production compared to basal (Fig. 4B) (n = 9–12, P < 0.001). In addition, CS-exposed mice infected 
with IAV had even greater PDBu-stimulated superoxide production compared to IAV-infected mice. Apocynin 
(5 mg kg−1) treatment caused a significant reduction in PDBu-stimulated superoxide in IAV-infected mice and 
CS + IAV mice (Fig. 4B) (n = 9–12, P < 0.001). However d7 PDBu-stimulated superoxide production was lower 
than that observed in d3 mice. Basal levels of superoxide were similar for all treatment groups.
Effects of apocynin on body weight and food consumption in cigarette smoke exposed and 
influenza A virus-infected mice. Mice exposed to CS for 4 days lost weight compared to sham-exposed 
mice (Fig. 5A,B). Apocynin (5 mg kg−1) treatment did not affect CS-induced weight loss. IAV infection caused a 
small amount of weight loss at days 3–5 post-infection compared to sham + diluent mice, but this was not statis-
tically significant (P > 0.05). In addition, IAV infection after CS exposure did not cause further significant weight 
loss compared to CS + diluent mice. Once again, apocynin (5 mg kg−1) treatment had no impact on body weight 
in sham + IAV mice and CS + IAV mice.
In general, the food consumption by CS-exposed mice was lower than the sham-exposed mice over the 
four-day smoking period (Fig. 5C,D). In addition, IAV infection didn’t impact on food intake nor did treatment 
with apocynin.
Figure 4. Effect of apocynin on superoxide radical production from BALF cells obtained from mice 
exposed to cigarette smoke (CS) and infected with influenza A virus (IAV). BALF cells recovered from 
apocynin (5 mg kg−1) or vehicle (0.1% DMSO) treated CS-exposed and IAV-infected mice 3 (A) and 7 (B) days 
post infection were assessed ex vivo for superoxide production under basal and PDBu-stimulated conditions. 
Data in relative light units(RLU)/second per 1000 cells are expressed as mean ± SEM for n = 9–12 mice. 
Statistical significance was assessed using two-way ANOVA and Bonferroni post-hoc test. *P < 0.05, #P < 0.001.
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Ebselen reduces BALF inflammation in cigarette smoke exposed and influenza A virus-infected 
mice. Mice exposed to CS and treated with diluent had a small increase in BALF total cell number, mac-
rophages and neutrophils when compared to sham + diluent mice at day 3 (Fig. 6A–D). Sham mice treated with 
IAV + vehicle had significantly more BALF total cells, macrophages, neutrophils and lymphocytes compared to 
sham + diluent + vehicle mice 3 days post infection (Fig. 6A–D, n = 6, P < 0.05). However, CS-exposed mice 
treated with IAV had significantly more BALF total cells, macrophages, neutrophils and lymphocytes when com-
pared to sham + IAV + vehicle mice (Fig. 6A–D, n = 6, P < 0.05). Administration of ebselen (10 mg kg−1) for 
3 days caused a significant decrease in BALF total cells, macrophages, neutrophils and lymphocytes in CS + IAV 
mice compared to CS + IAV + vehicle mice (Fig. 6A–D, n = 6–8, P < 0.05).
As in the d3 experiment, d7 CS + IAV mice had significantly more BALF total cells, macrophages, neutrophils 
and lymphocytes when compared to sham + IAV + vehicle mice (Fig. 7A–D, n = 6, P < 0.05). Administration of 
ebselen (10 mg kg−1) for 7 days caused a significant decrease in BALF total cells, macrophages, neutrophils and 
lymphocytes in CS + IAV mice compared to CS + IAV + vehicle mice (Fig. 7A–D, n = 6–8, P < 0.05). However 
Figure 5. Effect of apocynin on (A,B) body weight and (C,D) food consumption in mice exposed to cigarette 
smoke (CS) and infected with influenza A virus (IAV). Mice (n = 5–8) were weight matched into different 
treatment groups on day − 3 and then the body weight of each mouse was recorded daily throughout the 
experimental protocol until 7 days post infection (d7). Mice were treated with apocynin (5 mg kg−1) or vehicle 
(0.1% DMSO in PBS) i.p. 3 h before infection with 1 × 104.5 PFU of Mem71 virus and then daily thereafter. Food 
consumption was calculated by measuring the amount of food remaining in cages every 24 h and dividing that 
by the number of mice in the cages.
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d7 cell counts were lower than on d3 and therefore show that resolution of inflammation has occurred during 
these days.
Effect of ebselen administration on chemokines, cytokines and protease mRNA expression in 
cigarette smoke exposed and influenza A virus-infected mice. Since we had previously identified a 
panel of inflammatory genes that were markedly increased in the lungs of mice treated with the combination of 
CS and IAV, we next assessed whether ebselen had an inhibitory effect on their expression.
Three days post infection, sham + IAV + vehicle mice had increased mRNA expression of pro-inflammatory 
chemokines (CCL-2, CXCL-2, CXCL-10), cytokines (GM-CSF, TNF-α , IL-1β , IL-6) and proteases (MMP-12) 
compared to sham + diluent + vehicle mice. However, IAV mice treated with ebselen had markedly lower mRNA 
expression of chemokines (CCL-2, CXCL-2, CXCL-10), cytokines (GM-CSF, TNF-α , IL-1β , IL-6) and proteases 
(MMP-12) compared to IAV + vehicle mice (Table 3). CS + IAV + ebselen mice had reduced GM-CSF, IL-6 and 
MMP-12 but surprisingly increased TNF-α , IL-1β , CCL-2, CXCL-2 and CXCL-10 compared to CS + IAV + vehi-
cle mice (Table 3).
Seven days post infection, CS + IAV mice had increased mRNA expression of pro-inflammatory chemok-
ines (CCL-2, CXCL-2, CXCL-9, CXCL-10), cytokines (GM-CSF, TNF-α , IL-1β , IL-6) and proteases (MMP-
12) compared to sham + IAV + diluent mice or CS + diluent mice (Table 4). However, CS + IAV mice treated 
with ebselen for 7 days had markedly reduced mRNA expression of chemokines (CCL-2, CXCL-2, CXCL-9, 
CXCL-10), cytokines (GM-CSF, TNF-α , IL-1β , IL-6) and proteases (MMP-12) compared to CS + IAV + vehicle 
mice (Table 4).
Clearance of influenza A virus by ebselen following cigarette smoke exposure and influenza 
A virus infection. Plaque assays on lung homogenates were used to determine the amount of virus in 
the lungs of mice infected with IAV. As seen in Fig. 3B, there was a considerable amount of virus present in 
sham + IAV mice 3 days post infection. Moreover, CS exposure caused a significant increase in viral titre com-
pared to sham + IAV mice (n = 4–6, P < 0.05) and ebselen caused a significant decrease in the amount of virus in 
CS + IAV mice (n = 4–6, P < 0.05). In contrast, there was very little virus present in the lungs of sham + IAV mice 
7 days post infection and this was comparable to CS + IAV mice (n = 6, data not shown).
Effect of ebselen on body weights and food consumption in cigarette smoke exposed  and influ-
enza A virus-infected mice. Mice exposed to CS for 4 days lost weight compared to sham-exposed mice 
Figure 6. The effect of 3 day ebselen (10 mg kg−1) administration on BALF cells in mice after exposure to 
cigarette smoke (CS) and infection with influenza A virus (IAV). BALF cellularity is shown as (A) the total 
number of cells, (B) macrophages, (C) neutrophils and (D) lymphocytes. Data are expressed as mean ± SEM 
for n = 6–8 mice per treatment group. Two-way ANOVA with Bonferroni post-hoc test was performed to assess 
statistical significance. *P < 0.05, ***P < 0.001, #P < 0.05, ##P < 0.01, ###P < 0.001.
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(Fig. 8). Ebselen (10 mg kg−1) treatment did not affect CS-induced weight loss (P > 0.05). IAV infection caused a 
small amount of weight loss at days 3–6 post infection compared to sham + diluent mice, but this was not statis-
tically significant (P > 0.05). However, it appeared that CS + IAV mice weighed less than CS alone mice on days 
4–6 post infection. Once again, ebselen (10 mg kg−1) treatment had no impact on body weight in sham + IAV 
mice and CS + IAV mice.
Figure 7. The effect of 7 day ebselen (10 mg kg−1) administration on BALF cells in mice after exposure to 
cigarette smoke (CS) and infection with influenza A virus (IAV). BALF cellularity is shown as (A) the total 
number of cells, (B) macrophages, (C) neutrophils and (D) lymphocytes. Data are expressed as mean ± SEM for 
n = 6–8 mice per treatment group. Two-way ANOVA with Bonferroni post-hoc test was performed to assess 
statistical significance. *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.05, ##P < 0.01, ###P < 0.001.
Treatment
Gene
Sham CS
Dil + Veh Dil + Ebs IAV + Veh IAV + Ebs Dil + Veh Dil + Ebs IAV + Veh IAV + Ebs
Cytokines
 GM-CSF 1.00 2.78 11.16 5.47 6.56 4.24 8.57 6.24
 TNF-α 1.00 1.28 16.73 7.71 3.49 1.70 13.29 28.47
 IL-1β 1.00 3.27 10.15 5.15 1.59 0.99 5.59 10.11
 IL-6 1.00 2.53 295.99 123.56 5.46 7.52 128.63 98.91
Chemokines
 CCL-2 1.00 3.12 485.73 318.35 11.17 15.00 303.96 370.88
 CXCL-2 1.00 1.91 59.45 41.18 8.44 7.42 31.57 38.96
 CXCL-10 1.00 1.93 517.05 282.40 4.03 2.62 230.38 404.87
Proteases
 MMP-12 1.00 2.88 23.31 11.88 67.20 81.80 124.07 109.27
Table 3.  Effect of ebselen administration on whole lung cytokine, chemokine and protease mRNA 
expression in cigarette smoke (CS) and influenza A virus (IAV)-infected mice (3 days post infection). 
mRNA expression for all genes was measured simultaneously under identical conditions using quantitative 
real-time PCR. Responses for each time point are shown as fold change relative to sham + dil + veh mice after 
normalization to 18S rRNA (housekeeping gene). Data are shown as the average for duplicate reactions of 6–8 
pooled whole lungs.
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In general, the food consumption by CS-exposed mice was lower than the sham-exposed mice over the 
four-day smoking period (Fig. 8C,D). In addition, IAV infection didn’t really impact on food intake nor did 
treatment with ebselen.
Discussion
The primary aim of this study was to determine whether targeting oxidative stress with apocynin and ebse-
len could reduce lung inflammation in mice exposed to CS and infected with IAV, using an in vivo model that 
mimics AECOPD. We found that apocynin and ebselen generally reduced BALF inflammation, whole lung 
pro-inflammatory mediators and proteases, that ebselen reduced the amount of virus in the lungs but that neither 
apocynin nor ebselen affected CS and IAV-induced weight loss or food intake.
In the present study we found that CS-exposed mice had increased BALF total cells, macrophages and neu-
trophils compared to sham-treated mice. IAV infection alone also caused an increase in BALF macrophages and 
neutrophils but this was further amplified with prior CS exposure. These observations are consistent with previ-
ous studies showing that CS exacerbates the inflammatory response to IAV infection10,37.
We then went on to explore the mechanisms responsible for this increased BALF inflammation in CS + IAV 
mice. CS contains high levels of oxidants, which can increase BALF cellularity through cell recruitment, 
increased cell proliferation, and by prolonging cell survival in the airways38,39. Influenza A infection also causes 
the production of oxidants which further add to the oxidative burden induced by CS. Oxidants then activate 
redox sensitive transcription factors (such as NF-κ B and AP-1) which lead to an increase in gene expression of 
pro-inflammatory cytokines and chemokines which are responsible for cell recruitment, survival and prolifer-
ation40. Since pro-inflammatory chemokine, cytokines and proteases regulate lung inflammation, we examined 
the expression of a wide range of pro-inflammatory mediators following CS exposure and influenza infection. CS 
exposure resulted in increased mRNA levels of cytokines (GM-CSF, TNF-α , IL-1β , IL-6), chemokines (CCL-2, 
CXCL-2, CXCL-10) and proteases (MMP-12). In addition, influenza infection in CS-exposed mice resulted in 
increased production of these pro-inflammatory cytokines, chemokines and proteases. Macrophages and neu-
trophils are increased in patients with COPD and further augmented following influenza infection11,40. Moreover, 
macrophages in lungs can be directly activated by CS to release inflammatory mediators such as CCL-2, which 
recruits monocytes from blood to increase the airway alveolar macrophage population41. Furthermore, activation 
and survival of neutrophils and macrophages are promoted by TNF-α and GM-CSF35,36,42. Therefore, the increase 
in CCL-2, TNF-α and GM-CSF in our study may explain the observed increase in macrophages and neutrophils 
following CS and influenza infection.
A potential limitation of our study is that we only measured mRNA levels of various cytokines, chemokines 
and proteases but did not measure protein levels of these mediators. Based on our previous study of BALF protein 
measurements in a similar model10, there was a poor correlation with mRNA levels and cytokine BALF levels 
in general were very low, as the increase in inflammation may cause increased consumption of BALF cytokines. 
We have previously published that CS exposure (without viral infection) was associated with higher protein 
levels of TNF-α , MIP-2, GM-CSF and IFN-γ in BALF than in no-smoke mice, especially at d1010. Also, IAV 
increased d3 protein levels of MIP-2 and MCP-1 more so with prior CS exposure. IAV infection alone did not 
increase other cytokines in BALF. However, when comparing IAV alone to CS and IAV mice, CS reduced the 
IAV-associated induction of mRNA encoding TNF-α , IL-1β , IL-6, and IP-10 at d3 and MIG (monokine induced 
by gamma-interferon) at d10. CS increased the IAV-associated induction of mRNA encoding IL-17. We also 
found that mRNA and protein levels for the same mediator were often not concordant; many of these inflamma-
tory mediators may be subject to post-transcriptional regulation. Alternatively, given that mRNA and protein 
Treatment
Gene
Sham CS
Dil + Veh Dil + Ebs IAV + Veh IAV + Ebs Dil + Veh Dil + Ebs IAV + Veh IAV + Ebs
Cytokines
 GM-CSF 1.00 1.14 2.71 2.14 0.07 0.07 12.32 9.71
 TNF-α 1.00 0.92 2.19 3.12 0.32 0.36 20.50 12.82
 IL-1β 1.00 0.94 1.05 1.36 0.31 0.30 7.92 5.67
 IL-6 1.00 0.98 0.57 0.91 0.09 0.10 3.10 2.5
Chemokines
 CCL-2 1.00 1.14 2.71 2.14 0.07 0.07 12.32 9.71
 CXCL-2 1.00 0.75 1.86 2.60 0.25 2.70 3.12 2.12
 CXCL-10 1.00 1.05 14.75 27.12 0.24 0.37 153.53 122.86
Proteases
 MMP-12 1.00 0.84 0.44 0.05 1.34 1.27 14.59 8.87
Table 4.  Effect of ebselen administration on whole lung cytokine, chemokine and protease mRNA 
expression in cigarette smoke (CS) and influenza A virus (IAV)-infected mice (7 days post infection). 
mRNA expression for all genes was measured simultaneously under identical conditions using quantitative 
real-time PCR. Responses for each time point are shown as fold change relative to sham + dil + veh mice after 
normalization to 18 S rRNA (housekeeping gene). Data are shown as the average for duplicate reactions of 6–8 
pooled whole lungs.
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levels under certain conditions do not correlate then perhaps protein levels of the various mediators would be the 
better marker of inflammation and could likely contribute to the impaired immune response.
In the present study we found that CS + IAV mice had increased levels of lymphocytes compared to CS or IAV 
alone mice. This is consistent with findings in both animals10,37 and subjects with AECOPD8. It is probable that 
the observed increases in lymphocytes were due to increased CXCL-10 expression, a known chemotactic factor 
for lymphocytes. This is important as CD8+ T cells are critical for a protective memory response following influ-
enza infection but when produced in excess can be involved in tissue damage in smokers43,44. Moreover, CD4+ T 
cells are involved in hypersecretion in smokers, which are known but not essential for clearance of influenza in 
mice45.
Neutrophils in COPD and AECOPD have the capacity to induce tissue damage through secretion of pro-
teases46. In this study, there was an upregulation of matrix metalloproteinase 12 (MMP-12). The increased expres-
sion of MMP-12 in our study are in accord with COPD patients who have increased levels of MMP-12 in their 
lungs compared to healthy subjects without COPD47. Moreover, it has been shown that emphysema caused by 
chronic CS exposure is prevented in MMP-12−/− mice48, suggesting that MMP-12 can have a destructive role 
Figure 8. Effect of ebselen on (A,B) body weight and (C,D) food consumption in mice exposed to cigarette 
smoke (CS) and infected with influenza A virus (IAV). Mice (n = 6–8) were weight matched into different 
treatment groups on day − 3 and then the body weight of each mouse was recorded daily throughout the 
experimental protocol until 7 days post infection (d7). Mice were treated with ebselen (10 mg kg−1) or vehicle 
(5% CM-cellulose) by oral gavage 3 h before infection with 1 × 104.5 PFU of Mem71 virus and then daily 
thereafter. Food consumption was calculated by measuring the amount of food remaining in cages every 24 h 
and dividing that by the number of mice in the cages.
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in AECOPD. While our study focussed mainly on the impact of apocynin and ebselen on BALF inflammation, 
cytokine/chemokine/protease/ROS production, and viral load, it would be interesting to assess the effects of these 
compounds on chronic features of COPD (such as emphysema and changes in lung function) using models like 
those described by Beckett and colleagues49.
The increased BALF inflammation observed in our study may also be because existing mechanisms, such as 
production of endogenous anti-oxidants, to resolve lung inflammation are overwhelmed. Moreover, Robbins 
and colleagues showed that CS exposure with high dose of IAV infection increased the inflammatory response in 
lungs, in contrast to low dose of IAV infection, which resulted in decreased airway inflammation11.
Glutathione peroxidases (GPx) are cytosolic selenium-dependent and independent anti-oxidant enzymes 
that play a critical role maintaining and protecting bio-membranes against oxidative stress in various disease 
states50,51. Previous studies have shown that GPx-1 protects against CS and IAV (HKx31)-induced lung inflam-
mation29,30. Moreover, the GPx mimetic ebselen has been shown to be protective in vivo in disease states hall-
marked by oxidative stress such as diabetes-associated atherosclerosis, cerebral ischemia-reperfusion injury and 
lung inflammation29−31,52,53. In particular, ebselen reduces LPS-induced lung inflammation by reducing the levels 
of TNF-α and MIP-2, potent inducers of neutrophil activation32. In addition, ebselen has been used in clinical 
trials of acute ischemic stroke54,55. Specifically, Yamaguchi et al.55 explored the effects of ebselen on the outcome 
of acute ischemic stroke in a multi-center, placebo-controlled, double-blind clinical trial. They demonstrated 
that early treatment (i.e., patients who started ebselen within 24 h of stroke onset) with ebselen (150 mg bid) 
improved the outcome of acute ischemic stroke55. Similarly, Ogawa et al.54 showed in a randomized, double-blind, 
placebo-controlled trial of ebselen conducted in patients with complete occlusion of the middle cerebral artery 
that ebselen protected the brain from ischemic damage in the acute stage. More recently, ebselen has been trialled 
for prevention and treatment of noise-induced hearing loss (see ClinicalTrials.gov identifier: NCT01444846). 
Given the above, we expected that mice treated with ebselen would show a reduction in lung inflammation fol-
lowing CS and IAV infection. This was indeed the case and also attributed to its inhibitory effect on the various 
chemotactic factors and proteases involved in recruiting inflammatory cells into the lungs.
To further investigate the role of oxidative stress in this in vivo model of AECOPD, we used a pharmacological 
inhibitor of Nox-2, apocynin. Apocynin has been shown to have beneficial effects in a number of disease mod-
els including hypertension56, myocardial infarction57, asthma58 and influenza infections18. In addition, Orosz 
et al. has shown that apocynin can prevent CS-induced endothelial dysfunction and hinder the NADPH oxidase 
derived H2O2 generation in endothelial and smooth muscle cells59. The effects of apocynin on ROS production in 
human asthma and COPD have also been explored. Specifically, nebulized apocynin reduced the levels of H2O2 
and nitrite (NO2−) ions in the EBC of COPD patients34. It has also been shown that nebulised apocynin signif-
icantly decreased the levels of H2O2, NO2− and nitrate (NO3−) in EBC from asthmatic subjects33. These studies, 
and one performed in healthy subjects60, showed that apocynin is well tolerated and had no adverse events. 
Collectively, these studies suggest that apocynin may have potential for the treatment of bronchial asthma and 
COPD. Therefore, as anticipated, we found that apocynin reduced BALF cellularity, inflammatory gene expres-
sion and superoxide production in CS + IAV treated mice, highlighting the importance of redox-dependent 
inflammatory signalling in the lung.
Given that ROS are required for host defence against invading pathogens, it is conceivable that the suppres-
sion of ROS with pharmacological agents such as apocynin could increase susceptibility to secondary bacterial 
exacerbations. The evidence to support this possibility comes from studies of patients with a rare condition (1 in 
200,000) known as chronic granulomatous disease (CGD). CGD patients have an ‘underactive’ ROS generating 
system in which their leukocytes are unable to mount a respiratory burst, leaving them susceptible to severe, 
life-threatening infections by opportunistic microbes such as bacteria and fungi61. CGD can be caused by sev-
eral mechanisms including missense, nonsense, frameshift, splice and deletion mutations in the genes for Nox2, 
p22phox, p47phox, p67phox or p40phox. Depending on the type of mutation, superoxide production may range from 
being ~0.1% to 10% of normal production62. A recent key study by Kuhns et al. provides evidence that CGD 
patients with mutations causing even modest residual ROS production (~1% of the normal amount) have a sub-
stantial survival benefit and antipathogen capabilities62. Indeed, an appropriate dosage of an inhibitor of Nox2 
to reduce, rather than abolish, NADPH oxidase activity could be used feasibly without compromising the innate 
immune system in patients with IAV-induced lung oxidative stress and pathology. In addition, partial inhibition 
of ROS could be achieved by utilising inhibitors that target p47phox. Indeed, mutations in p47phox - as observed in 
the study of Kuhns et al.62 - provide evidence that the oxidase is still capable of producing sufficient amounts of 
superoxide to serve anti-pathogen roles. In this study, and in our previously published work18, we have shown 
that apocynin decreases superoxide production in BALF inflammatory cells obtained from IAV-infected mice by 
approximately 30–50%. This is important as the remaining superoxide will serve anti-pathogen roles and should 
protect the host against susceptibility to bacterial exacerbations.
To determine if the exacerbated inflammatory response is due to greater viral replication and if the 
anti-oxidants have an effect in viral clearance, we assessed the amount of virus in the lungs. In accordance with 
our previous work10, sham + IAV mice had increased viral titres and this was further exacerbated in CS + IAV 
mice. However, apocynin did not affect viral load in lungs from IAV or CS + IAV mice. This is in contrast to our 
findings where apocynin reduced viral load in HKx31-infected mice18 suggesting that the effects of apocynin 
may depend on the strain of IAV used. In contrast to apocynin, CS + IAV mice treated with ebselen had signif-
icantly lower viral titres than CS + IAV + vehicle mice. This may be due to the increased levels of CXCL-10 and 
the anti-viral cytokine IFN-γ (data not shown) we observed in whole lungs of CS + IAV + ebselen mice com-
pared with CS + IAV + vehicle mice. Furthermore, increased neutrophil numbers correlate with the enhanced 
viral clearance in IAV-infected mice63, but this was not the case in our study as neutrophils were reduced in 
ebselen-treated mice. This would suggest that ebselen potentially interfered with viral replication at a very early 
stage resulting in reduced cytokine production and reduced neutrophils. Another possibility is that virus specific 
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CD8 + T cells can play a role in clearance of influenza virus10, but these were not measured in the present study. 
Recently, Hsu et al. showed that the increased susceptibility of individuals with COPD to influenza likely results 
from impaired antiviral responses, which are mediated by increased PI3K-p110α activity64.
Cigarette smoke-mediated weight loss is well documented in the literature and this was confirmed in the 
present study. However, the combination of CS + IAV had no further effect on body weight nor did treatment 
with apocynin or ebselen. Increases in pro-inflammatory cytokines such as TNF-α have been observed in COPD 
and it could be that TNF-α regulates lipid metabolism by releasing leptin from adipose tissues65. This in turn acts 
on the neuropeptide Y in the hypothalamus to suppress appetite thereby leading to the weight loss65 observed in 
our study. Conversely, our findings that Mem71 flu infection did not affect body weight in mice is in accordance 
with other studies10, as it is of intermediate virulence despite its ability to induce a strong immune response. In 
addition, it would have been worth evaluating whether apocynin and ebselen influenced IAV-induced morbidity 
using a higher dose of Mem71 or alternatively using a more virulent strain of IAV such as A/PR/8/3464. This is 
important because if apocynin and ebselen improve the health of IAV-infected mice, then this would further add 
to the therapeutic potential of these compounds.
In conclusion, we found that in this animal model of CS and IAV (Mem71) infection, apocynin and ebselen 
reduced oxidative stress, the expression of pro-inflammatory mediators in the lung, BALF lung inflammation and 
viral titres but had no effect on CS and IAV-induced weight loss and food intake. The striking effects of apocynin 
and ebselen in our model suggest that they could be of important value in attenuating inflammation and improv-
ing viral clearance in AECOPD by targeting oxidative stress, either alone or when added to conventional therapy.
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